- $11.49bn
- $10.56bn
- $2.76bn
- 90
- 49
- 86
- 89
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 974 | 1,453 | 2,107 | 2,516 | 2,762 |
Cost of Revenue | |||||
Gross Profit | 731 | 1,089 | 1,641 | 1,981 | 2,190 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,167 | 1,661 | 2,169 | 2,604 | 2,730 |
Operating Profit | -194 | -208 | -61.9 | -88 | 31.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -204 | -229 | -66.9 | -89.9 | 93.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -208 | -243 | -70 | -97.5 | 74 |
Net Income Before Extraordinary Items | |||||
Net Income | -208 | -243 | -70 | -97.5 | 74 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -208 | -243 | -70 | -97.5 | 74 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.18 | -1.16 | -0.338 | -0.37 | 0.486 |